← Back to Search

Paroxysmal Atrial Fibrillation Patients for Atrial Fibrillation

N/A
Waitlist Available
Led By Hamid Ghanbari, MD
Research Sponsored by Verily Life Sciences LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 14 days
Awards & highlights

Summary

This study is designed to evaluate the performance of the Verily Watch Cardio for recording electrocardiogram (ECG) and photoplethysmography (PPG) signals and detecting suspected atrial fibrillation (AF) episodes, in a free-living environment, in participants at risk for having an AF event.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 14 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 14 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Sensitivity and Specificity of suspected AF episode detection
Secondary study objectives
A sensitivity analysis estimating the range of sensitivities and specificities
Mean difference in Interbeat interval (IBI) and the associated limits of agreement (LoA)
Participant-level and heartbeat level sensitivity/specificity of P-wave detection
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Paroxysmal Atrial Fibrillation PatientsExperimental Treatment3 Interventions

Find a Location

Who is running the clinical trial?

Verily Life Sciences LLCLead Sponsor
16 Previous Clinical Trials
24,570 Total Patients Enrolled
2 Trials studying Atrial Fibrillation
277 Patients Enrolled for Atrial Fibrillation
Hamid Ghanbari, MDPrincipal InvestigatorVerily Life Sciences
1 Previous Clinical Trials
131 Total Patients Enrolled
1 Trials studying Atrial Fibrillation
131 Patients Enrolled for Atrial Fibrillation
~0 spots leftby Sep 2025